GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » EV-to-EBIT

Renovacor (Renovacor) EV-to-EBIT : -0.08 (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Renovacor's Enterprise Value is $3.07 Mil. Renovacor's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-37.80 Mil. Therefore, Renovacor's EV-to-EBIT for today is -0.08.

The historical rank and industry rank for Renovacor's EV-to-EBIT or its related term are showing as below:

RCOR' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.58   Med: 0   Max: 3.8
Current: -0.08

During the past 2 years, the highest EV-to-EBIT of Renovacor was 3.80. The lowest was -9.58. And the median was 0.00.

RCOR's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 9.61 vs RCOR: -0.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Renovacor's Enterprise Value for the quarter that ended in Sep. 2022 was $-9.93 Mil. Renovacor's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-37.80 Mil. Renovacor's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was 380.66%.


Renovacor EV-to-EBIT Historical Data

The historical data trend for Renovacor's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor EV-to-EBIT Chart

Renovacor Annual Data
Trend Dec20 Dec21
EV-to-EBIT
- -2.79

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only -4.98 -2.79 -0.04 0.90 0.26

Competitive Comparison of Renovacor's EV-to-EBIT

For the Biotechnology subindustry, Renovacor's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovacor's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Renovacor's EV-to-EBIT falls into.



Renovacor EV-to-EBIT Calculation

Renovacor's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3.074/-37.796
=-0.08

Renovacor's current Enterprise Value is $3.07 Mil.
Renovacor's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renovacor  (AMEX:RCOR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Renovacor's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=-37.796/-9.929112
=380.66 %

Renovacor's Enterprise Value for the quarter that ended in Sep. 2022 was $-9.93 Mil.
Renovacor's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renovacor EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Renovacor's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovacor (Renovacor) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines